Importantly, the addition of a PDK1 inhibitor to CDK4/6 inhibitor treatment reversed the resistance in ER+ breast cancer cell lines, and both PDK inhibition, as well as PI3K inhibition, potentiated the effect of a CDK4/6 blockade in xenograft models. The gene discussed is CDK4; the disease is breast carcinoma.